INOTAD(Irinotecan)
Therapeutic class: topoisomerase inhibitor
- First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
- Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
40 mg & 100 mg Injection
40 mg:- A vial of 40 mg100 mg:- A vial of 100 mg
- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
